Phathom Pharmaceuticals/$PHAT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Ticker

$PHAT
Sector
Primary listing

Employees

427

PHAT Metrics

BasicAdvanced
$848M
-
-$4.71
0.45
-

What the Analysts think about PHAT

Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.

Bulls say / Bears say

VOQUEZNA recorded more than 390,000 prescriptions filled and $28.5 million in net revenue in Q1 2025, pointing to strong early demand.
The FDA's Orange Book update grants VOQUEZNA full 10-year New Chemical Entity exclusivity until May 3, 2032, ensuring a lengthy period without generic competition.
VOQUEZNA demonstrates high profitability potential, highlighted by an 86.23% trailing twelve-month gross margin, indicating strong pricing power and efficient costs.
Phathom reported a net loss of $94.3 million in Q1 2025, showing the company remains unprofitable despite strong initial sales.
General and administrative expenses jumped to $94.5 million in Q1 2025, up 52% year-over-year, raising concerns about cost control and cash burn.
The company halted its planned Phase 2 trial for eosinophilic esophagitis, delaying pipeline expansion and future growth potential due to exclusivity and funding challenges.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

PHAT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PHAT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHAT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs